Proton Pump Inhibitors in Veterinary Medicine

Yavuz, Oğuzhan; Arslan, Handan Hilal

doi:10.3844/ajavsp.2017.132.138

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, administering omeprazole twice daily to healthy dogs for 15 days resulted in quantifiable changes in the gastric, duodenal, and fecal microbiome, accompanied by a significant increase in gastric pH and altered bacterial composition. Lactobacillus bacteria were notably elevated in the duodenum and fecal samples in male dogs during omeprazole therapy without qualitative changes in fecal composition [6,14]. Changes in pharyngeal flora, including Staphylococcus spp., Bacillus spp., and Pasteurella spp.…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Prospective Randomized Controlled Clinical Trial of the Long-Term Effects of Omeprazole on Healthy Dogs

Gil-Vicente,

Martín,

Soler

et al. 2024

Animals

View full text Add to dashboard Cite

The use of omeprazole as a preventive treatment for gastrointestinal ulcers in veterinary medicine has been questioned during previous years. The aim of the present study is to assess the long-term effect of omeprazole on cobalamin and serum gastrin levels in healthy dogs. Eighteen healthy dogs were included: 10 in the control group and 8 in the omeprazole group. Three samples were collected: before starting the treatment (T0), 30 days after the start of treatment (T1), and at 60 days (T2). The mean cobalamin value (ng/L) in the control group was 481.4 (±293.70) at T0, 481.4 (±170.21) at T1, and 513.2 (±174.50) at T2. In the omeprazole group, the values were 424.62 (±161.57) at T0, 454.5 (±160.96) at T1, and 414.87 (±127.90) at T2. No statistically significant changes were detected in cobalamin levels between the three-time period in both study groups. These results agree with previous findings in felines but contrast with human medicine studies. The median gastrin values (pg/mL) in the control group were 62.45 [30.17–218.75] at T0, 76.06 [30.67–199.87] at T1, and 63.02 [35.81–176.06] at T2. The median gastrin value in the omeprazole group was 67.59 [55.96–101.60] at T0, 191.77 [75.31–1901.77] at T1, and 128.16 [43.62–1066.46] at T2. Statistically significant differences were detected (p = 0.008), indicating an increase in gastrin levels after initiating treatment with omeprazole. In conclusion, the increased levels of gastrin observed in this population underscore the importance of conducting a comprehensive clinical assessment to identify potential gastrointestinal disorders, particularly in consideration of the usage of omeprazole as a preventive treatment.

show abstract

Section: Introductionmentioning

confidence: 97%

“…It is metabolized rapidly and completely by the liver, by cytochrome P 450 enzymes (CYP 450 ), and eliminated through the urine [1]. Administration can be either parenteral or enteral, with rapid absorption in the small intestine and peak plasmatic concentrations observed three hours post-administration [6].…”

Section: Introductionmentioning

confidence: 99%